The Rapstrom Sirolimus Eluting Stent completed its 36 month registry reporting a good performance in single coronary lesions including high procedural success and efficacy as demonstrated, with no mace and no ST.
The excellent results of RAPSTROM registry is continuing to encourage us to evaluate RAPSTROM stent patients for its safety and efficacy.